LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

Elanco Animal Health Inc

Aperta

SettoreSettore sanitario

12.98 0.78

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.78

Massimo

12.98

Metriche Chiave

By Trading Economics

Entrata

75M

67M

Vendite

173M

1.2B

P/E

Media del settore

17.093

56.602

EPS

0.37

Margine di Profitto

5.616

Dipendenti

9,000

EBITDA

86M

261M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+13.06% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

1.6B

6.4B

Apertura precedente

12.2

Chiusura precedente

12.98

Notizie sul Sentiment di mercato

By Acuity

50%

50%

173 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Elanco Animal Health Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 mag 2025, 11:29 UTC

Acquisizioni, Fusioni, Takeovers

Elanco Sells Non-Core Asset to Blackstone for $295 Million

27 giu 2024, 14:34 UTC

I principali Market Mover

Elanco Shares Retreat Over Zenrelia Warning Label Concerns

5 mag 2025, 11:14 UTC

Acquisizioni, Fusioni, Takeovers

Elanco Sells Non-Core Asset to Blackstone for $295 Mln

5 mag 2025, 10:50 UTC

Acquisizioni, Fusioni, Takeovers

Elanco Animal Health: Monetization of This Non-Core Asset Will Be Used to Accelerate Debt Reduction >ELAN

5 mag 2025, 10:49 UTC

Acquisizioni, Fusioni, Takeovers

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone for $295M

9 lug 2024, 12:30 UTC

Acquisizioni, Fusioni, Takeovers

Merck Animal Health Completes Acquisition Of Elanco's Aqua Business >MRK

9 lug 2024, 12:29 UTC

Acquisizioni, Fusioni, Takeovers

Elanco Animal Health Sees Ending 2024 With Net Debt to Adjusted Ebitda in Mid-4x Range >ELAN

9 lug 2024, 12:28 UTC

Acquisizioni, Fusioni, Takeovers

Elanco Animal Health: $1.05B-$1.1B Net Proceeds Available for Debt Paydown in 3Q >ELAN

9 lug 2024, 12:28 UTC

Acquisizioni, Fusioni, Takeovers

Elanco Completes Sale of Aqua Business to Merck >ELAN MRK

Confronto tra pari

Modifica del prezzo

Elanco Animal Health Inc Previsione

Obiettivo di Prezzo

By TipRanks

13.06% in crescita

Previsioni per 12 mesi

Media 14.63 USD  13.06%

Alto 20 USD

Basso 10 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Elanco Animal Health Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.77 / N/ASupporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

173 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Elanco Animal Health Inc

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.